In summary, the current study provides novel evidence that KAT2B plays an important tumor suppressive role in cholangiocarcinoma through interaction with SP1 to enhance the expression of NF2 which leads to subsequent inhibition of oncogenic YAP. Here, SP1 is linked to cholangiocarcinoma.